- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

CATT Study Finds No Difference Between Avastin and Lucentis in Stopping Progression of Wet Macular Degeneration

Posted By Irv Arons On April 29, 2011 @ 5:19 am In Consultant Articles,Industry News,Macular Degeneration,Research,Retina | Comments Disabled

Yesterday, the New England Journal of Medicine released the much anticipated one-year results of The Comparison of AMD Treatment Trials (CATT) Study evaluating the relative effectiveness of Avastin (Bevacizumab) versus Lucentis (Ranibizumab) in stopping the progression of wet AMD and improving vision.

The study involved 1,185 patients being treated at 43 clinical centers in the United States. Patients were randomly assigned and treated with one of four regimens for a year. They received Lucentis monthly or as needed, or Avastin monthly or as needed.

The results showed that Avastin and Lucentis were equally effective and safe to use. Further, the study showed that “as needed” dosing does nearly as well (2 letter difference) as monthly injections.

To read my summary of the study, as well as Dr. Phil Rosenfeld’s editorial comments, please take a look at this link [1].

Click here [2] to read the write up of the study in the New England Journal of Medicine.


Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/005323-catt-study-finds-no-difference-between-avastin-and-lucentis-in-stopping-progression-of-wet-macular-degeneration/

URLs in this post:

[1] link: http://tinyurl.com/CATTUpdate14

[2] Click here: http://www.nejm.org/doi/full/10.1056/NEJMoa1102673

Copyright © 2008 Eye Doc Talk. All rights reserved.